T-Therapeutics Raises $133 Million In Series B Funding To Advance Cancer And Autoimmune Disease Treatments
By Amit Chowdhry ● Today at 10:05 AM
T-Therapeutics, a Cambridge, United Kingdom-based biotechnology company developing T cell receptor therapies for cancer and autoimmune diseases, has raised $133 million in an oversubscribed Series B financing round. The investment was co-led by Advent Life Sciences and British Business Bank, with participation from Johnson & Johnson Innovation – JJDC, Samsara BioCapital, M-Ventures, and Eli Lilly and Company. Existing major shareholders Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, and BGF also participated.